HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

BHQ880

a fully human, anti-DKK-1/Dickkopf-1 neutralizing antibody

Also Known As:

BHQ-880

Networked: 7 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Munshi, Nikhil C: 2 articles (11/2014 - 07/2009)
2.	Katoh, Masaru: 1 article (09/2017)
3.	Katoh, Masuko: 1 article (09/2017)
4.	Bautista Guzman, Wendy: 1 article (04/2016)
5.	Goldstein, Seth D: 1 article (04/2016)
6.	Hayashi, Masanori: 1 article (04/2016)
7.	Loeb, David M: 1 article (04/2016)
8.	Trucco, Matteo: 1 article (04/2016)
9.	Hajek, Roman: 1 article (03/2016)
10.	Jelinek, Tomas: 1 article (03/2016)

Related Diseases

1.	Multiple Myeloma 07/09/2009 - "Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma." 11/01/2014 - "A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events." 11/01/2014 - "BHQ880 in combination with zoledronic acid and anti-myeloma therapy was well tolerated and demonstrated potential clinical activity in patients with relapsed or refractory multiple myeloma. " 11/01/2014 - "BHQ880, a human neutralizing IgG1 anti-DKK1 monoclonal antibody, is being investigated for its impact on multiple myeloma-related bone disease and as an agent with potential anti-myeloma activity. "
2.	Neoplasms (Cancer) 09/01/2017 - "By contrast, Dickkopf-related protein 1 (DKK1), SOST and glycogen synthase kinase 3β (GSK3β) are targets of pro-WNT signaling therapy, and anti-DKK1 (BHQ880 and DKN-01) and anti-SOST (blosozumab, BPS804 and romosozumab) monoclonal antibodies are being tested in clinical trials for cancer patients and osteoporotic post-menopausal women. "
3.	Bone Diseases (Bone Disease) 07/09/2009 - "These results confirm DKK1 as an important therapeutic target in myeloma and provide the rationale for clinical evaluation of BHQ880 to improve bone disease and to inhibit MM growth." 03/01/2016 - "Monoclonal antibodies such as denosumab (anti-RANKL) or BHQ880 (anti-DKK-1) are investigated also in the management of myeloma bone disease. " 11/01/2014 - "BHQ880, a human neutralizing IgG1 anti-DKK1 monoclonal antibody, is being investigated for its impact on multiple myeloma-related bone disease and as an agent with potential anti-myeloma activity. "
4.	Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome) 07/09/2009 - "In a severe combined immunodeficiency (SCID)-hu murine model of human MM, BHQ880 treatment led to a significant increase in OB number, serum human osteocalcin level, and trabecular bone. "
5.	Osteosarcoma (Osteogenic Sarcoma) 04/19/2016 - "Treatment with the anti-DKK-1 antibody, BHQ880, slowed the growth of orthotopically implanted patient-derived osteosarcoma xenografts and inhibited metastasis. "

Related Drugs and Biologics

1.	Monoclonal Antibodies
2.	romosozumab
3.	Glycogen Synthase (Synthase I)
4.	Zoledronic Acid (Zometa)
5.	setrusumab
6.	blosozumab
7.	Catenins
8.	Osteocalcin
9.	Dihydrotestosterone (Androstanolone)
10.	Immunoglobulin G (IgG)

Related Therapies and Procedures

1.	Therapeutics